1
/
of
1
AntibodySystem
SKU:DHC34299
Telisotuzumab vedotin (ADC)
Telisotuzumab vedotin (ADC)
Regular price
$6,350.00 USD
Regular price
Sale price
$6,350.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Catalog No.: DHC34299
| Catalog No. | DHC34299 |
|---|---|
| Product name | Telisotuzumab vedotin (ADC) |
| Size | 5 mg |
| Species reactivity | Human |
| Applications | Research Grade Biosimilar |
| Description | Telisotuzumab vedotin is an ADC consisting of a cMET-directed antibody and Monomethyl auristatin E (MMAE) that has recently obtained the breakthrough therapy designation (BTD) for the treatment of patients with c-Met overexpression, advanced/metastatic wild-type (WT) epithelial growth factor receptor (EGFR) non-squamous non-small cell lung cancer (sqNSCLC) that progressed during or after platinum-based chemotherapy. |
| Form | Liquid |
| Purity | >90% as determined by SEC. |
| Clonality | Monoclonal |
| Target | cMet |
| Purification | Purified by Ion Exchange Chromatography. |
| Endotoxin level | Please contact with the lab for this information. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Alternative Names | ABBV-399 |
| Clone ID | Telisotuzumab vedotin |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
Share
